Kim Sung-Yong, Lee Jong-Wook, Lim Jihyang, Cho Byung-Sik, Eom Ki-Seong, Kim Yoo-Jin, Kim Hee-Je, Lee Seok, Min Chang-Ki, Cho Seok-Goo, Kim Dong-Wook, Min Woo-Sung, Kim Chun-Choo
Division of Hematology, Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea.
Biol Blood Marrow Transplant. 2007 Jul;13(7):863-70. doi: 10.1016/j.bbmt.2007.03.013. Epub 2007 May 24.
The outcome of unrelated donor bone marrow transplantation for aplastic anemia is inferior to that of sibling donor bone marrow transplantation because of a higher rate of transplant-related mortality (TRM), which is closely associated with the intensity of pretransplant conditioning to overcome graft rejection. We conducted a prospective trial with an intermediate to high dose of total body irradiation (TBI) in combination with a fixed dose of cyclophosphamide (120 mg/kg) to use for pretransplant conditioning for unrelated donor bone marrow transplantation in adult aplastic anemia. The number of patients who received doses of 1200, 1000, and 800 cGy of TBI were 5, 9, and 26, respectively. The corresponding probabilities of overall survival (OS) at 3 years were 40%, 44%, and 92%, respectively. The incidence of regimen-related toxicity with grade III-IV and graft rejection in the patients who received a dose of 800 cGy of TBI were 0 of 26 patients. The significant factors associated with OS were the TBI dose (800 cGy vs. >or=1000 cGy; P = .001), chronic graft-versus-host disease (less than or equal to limited vs. extensive; P = .013), the method of HLA typing for the donor-recipient matching (serologic typing vs. DNA-based typing; P = .006), and the transfusion amount before transplantation (<or=90 vs. >90 units; P = .020).
由于移植相关死亡率(TRM)较高,非血缘供者骨髓移植治疗再生障碍性贫血的疗效低于同胞供者骨髓移植,而TRM与为克服移植物排斥反应而进行的移植前预处理强度密切相关。我们开展了一项前瞻性试验,采用中高剂量全身照射(TBI)联合固定剂量环磷酰胺(120 mg/kg)用于成人再生障碍性贫血非血缘供者骨髓移植的移植前预处理。接受1200、1000和800 cGy TBI剂量的患者人数分别为5例、9例和26例。3年总生存率(OS)相应概率分别为40%、44%和92%。接受800 cGy TBI剂量的患者中,III-IV级方案相关毒性和移植物排斥反应的发生率在26例患者中为0。与OS相关的显著因素包括TBI剂量(800 cGy与≥1000 cGy;P = 0.001)、慢性移植物抗宿主病(局限性与广泛性;P = 0.013)、供受者匹配的HLA分型方法(血清学分型与基于DNA的分型;P = 0.006)以及移植前输血量(≤90单位与>90单位;P = 0.020)。